biocentury.com· BioCentury·· 2 days agoPickScore88
Merck and Moderna’s melanoma vaccine data bring adoption test into focus
In brief
Merck and Moderna's intismeran autogene combined with Keytruda (pembrolizumab) reduced the risk of recurrence or death by 42% in a Phase III melanoma trial (HR=0.58; p<0.001). The article focuses on adoption, weighing the added benefit against the anticipated cost and manufacturing complexity of an individualized therapy. The trial did not compare competing paths such as starting immunotherapy before surgery, a gap affecting its positioning in melanoma care.
Why it matters
Puts the 42% reduction in recurrence or death alongside manufacturing complexity, cost, and perioperative immunotherapy competition in melanoma vaccine adoption.
Source: biocentury.com · biocentury.com